KMTS · Kestra Medical Technologies, Ltd.

The thesis

Kestra Medical Technologies still has the evidence on its side: its wearable-defibrillator revenue grew 60% in the latest quarter and gross margin widened to 56.5%. The report estimated for 10 December 2026 settles whether the $141 million fiscal 2027 revenue guide holds. Heavy officer selling in late October is the main new counterweight.

No company results have arrived since the 14 September 2026 fiscal first-quarter report. Revenue was $31.0 million, up 60% from a year earlier, and gross margin was 56.5%, against 45.7% a year earlier. Kestra raised its fiscal 2027 revenue guide to $141 million from $137 million that day. The new facts since 22 October 2026 are higher analyst targets, a conference schedule and a run of Form 4 sales.

The narrative is maturing: eight analysts covered the shares by MarketBeat's 27 October 2026 count, no new results have appeared since 14 September 2026, and the shares are up only 0.6% over three months. The adjusted close was $28.53 on 5 November 2026, 6.8% below the $30.61 52-week high.

Bullish and bearish views on Kestra Medical Technologies, Ltd.

The bull case on Kestra Medical Technologies, Ltd. (KMTS), in brief: Revenue and guidance rose together. The bear case: Officers sold heavily in late October.

Bull case

• Revenue and guidance rose together. Kestra reported fiscal first-quarter revenue of $31.0 million on 14 September 2026 and lifted its fiscal 2027 guide to $141 million from the $137 million issued in July. Fiscal 2026 revenue was $95.1 million, up 59%.
• Gross margin keeps widening. Fiscal first-quarter gross margin reached 56.5% on 14 September 2026, up from 54.8% in the fiscal fourth quarter and 45.7% a year earlier. Management cited volume, a higher in-network patient mix and cost improvements.
• Analyst support has broadened. MarketBeat's 27 October 2026 summary shows five Buy, two Hold and one Sell ratings and a $29.00 average target, against four Buy and a $28.38 average from seven analysts earlier in October. Evercore ISI's $34 target from 20 October 2026 is the highest; J.P. Morgan and Royal Bank of Canada each carry $30.
• The shares made a new high in October. The 52-week high rose to $30.61 from $29.37 on 22 October 2026. Adjusted closes had been as low as $22.85 on 11 September 2026, just before the guidance raise.

Bear case

• Officers sold heavily in late October. SEC Form 4 filings summarized by Massive show officer Traci S. The same summary lists Chief Financial Officer Vaseem Mahboob selling 79,500 shares near $30.30, about $2.4 million, in a Form 4 filed 29 October 2026.
• MarketBeat counted 361,928 insider shares sold, worth $9,158,873, over the 90 days to 27 October 2026.
• Losses are widening. The fiscal first-quarter net loss was $44.1 million, against $25.8 million a year earlier. Loss per share of $0.75 missed the $0.61 consensus, according to MarketBeat.
• Share gains are not measured directly. Kestra attributed growth to market expansion, competitive share gains, new territories, patient mix and collection improvements. The 14 September 2026 release gave no new count of ASSURE prescriptions; the last count was 6,357 for the quarter ended 30 April 2026.
• The guide leans on later quarters. The original $137 million guide implied 44% growth in fiscal 2027, down from 59% in fiscal 2026. Management said on the 14 July 2026 call that growth should accelerate from the first half to the second half as recently hired sales representatives ramp.

Price setup

The adjusted close was $28.53 on 5 November 2026, 6.8% below the 52-week high of $30.61. That close sits below the $30.03 to $30.30 prices at which officers sold around 27 October 2026, and just below MarketBeat's $29.00 average analyst target. The shares rose 0.6% over three months, and the 14-day Relative Strength Index (a momentum gauge running from 0 to 100) is 55.0, near the middle of its range.

MarketBeat put the 50-day moving average at $26.51 and the 200-day at $23.73 on 27 October 2026, with a market value of $1.75 billion. The $24 invalidation level sits above the $22.85 close of 11 September 2026, the low before the guidance raise.

Crowding shows up mainly in insider supply and in the shares' proximity to analyst targets. The sales above came within weeks of the 52-week high, and all four late-October entries in Massive's summary are marked as pre-arranged plan sales. No share issuance has been announced since the 14 September 2026 report in company news reviewed for this note.

Catalysts, next 30 days

• 10 November 2026, 2:40 p.m. Eastern: Wolfe Research Healthcare Conference presentation, per Kestra's 30 October 2026 release.
• 11 November 2026, 2:00 p.m. Eastern: Stifel Healthcare Conference presentation, per the same release.
• 1 December 2026, 11:00 a.m. Eastern: Piper Sandler 38th Annual Healthcare Conference presentation, per the same release.
• ~10 December 2026, est.: Fiscal second-quarter 2027 report, just outside the 30-day window. Kestra has not confirmed the date; last year it announced the date on 3 December 2025 and reported on 11 December 2025. The quarter closed on 31 October 2026.

What would change the view

A cut to the $141 million fiscal 2027 revenue guide would break the case. So would fiscal second-quarter revenue growth falling well below the 60% pace, or gross margin slipping back from 56.5% while the net loss stays above the year-earlier level.

Insider selling outside pre-arranged plans would weaken the case, because plan sales were set in advance and fresh discretionary sales would reflect a current choice. On price, a weekly close below $24 would put the shares under the recovery range that followed the 14 September 2026 guidance raise and would end the thesis.

The case would strengthen if the December report raises the guide again and Kestra discloses a new ASSURE prescription count showing volume growth.

What it trades with

MarketBeat listed a beta of 0.51 on 27 October 2026, meaning the shares have moved less than the broad market. The largest dated moves in this note follow company events: the 14 September 2026 report and the 20 October 2026 Evercore ISI initiation. The next three months should therefore turn more on the December report than on the market. That view fails if the shares close a week below $24 on a broad medical-technology decline with no company news.